Esomeprazole, omeprazole sulfone, 5-O-desmethyl omeprazole and 5-hydroxylansoprazole are in vitro metabolism-dependent inhibitors of CYP2C19

Scientific Resources Esomeprazole, omeprazole sulfone, 5-O-desmethyl omeprazole and 5-hydroxylansoprazole are in vitro metabolism-dependent inhibitors of CYP2C19

• Published on September 14, 2011
• Drug Metabolism
• Enzyme Inhibition
• Scientific Posters

Full Title

Esomeprazole, omeprazole sulfone, 5-O-desmethyl omeprazole and 5-hydroxylansoprazole are in vitro metabolism-dependent inhibitors of CYP2C19

Abstract

The intensively researched interaction between clopidogrel and proton pump inhibitors (PPIs) and the impact of CYP2C19 poor metabolizer phenotype on clopidogrel efficacy have prompted warnings from the FDA and EMA in recent years (2010). The FDA specifically warns against coadministration of clopidogrel and omeprazole and further specifically suggests that pantoprazole may be a safer alternative (2010).

Download Poster